CN115916239A - 用于靶向治疗性递送至骨的组合物和方法 - Google Patents

用于靶向治疗性递送至骨的组合物和方法 Download PDF

Info

Publication number
CN115916239A
CN115916239A CN202180042758.XA CN202180042758A CN115916239A CN 115916239 A CN115916239 A CN 115916239A CN 202180042758 A CN202180042758 A CN 202180042758A CN 115916239 A CN115916239 A CN 115916239A
Authority
CN
China
Prior art keywords
seq
sequence
chimeric polypeptide
identity
polypeptide comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180042758.XA
Other languages
English (en)
Chinese (zh)
Inventor
路易斯·阿尔瓦雷斯
大卫·斯图尔特
海厄温·帕克
托德·海尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Treatment Adjustment Co
Original Assignee
Treatment Adjustment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Treatment Adjustment Co filed Critical Treatment Adjustment Co
Publication of CN115916239A publication Critical patent/CN115916239A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
CN202180042758.XA 2020-04-15 2021-04-14 用于靶向治疗性递送至骨的组合物和方法 Pending CN115916239A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063010639P 2020-04-15 2020-04-15
US63/010,639 2020-04-15
PCT/US2021/027230 WO2021211683A2 (en) 2020-04-15 2021-04-14 Compositions and methods for targeted therapeutic delivery to bone

Publications (1)

Publication Number Publication Date
CN115916239A true CN115916239A (zh) 2023-04-04

Family

ID=78084414

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180042758.XA Pending CN115916239A (zh) 2020-04-15 2021-04-14 用于靶向治疗性递送至骨的组合物和方法

Country Status (10)

Country Link
US (2) US12264187B2 (https=)
EP (1) EP4135750A4 (https=)
JP (2) JP2023525960A (https=)
KR (1) KR102821039B1 (https=)
CN (1) CN115916239A (https=)
AU (1) AU2021254751B2 (https=)
BR (1) BR112022020809A2 (https=)
CA (1) CA3180156A1 (https=)
TW (1) TW202203961A (https=)
WO (1) WO2021211683A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120789330A (zh) * 2025-08-04 2025-10-17 中国人民解放军总医院第四医学中心 一种外科钛合金融合器活性涂层的制备方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
CN113166202B (zh) 2018-10-12 2024-09-13 治疗调适公司 包括β-磷酸三钙-结合序列的多肽及其用途
JP2023525960A (ja) 2020-04-15 2023-06-20 セラダプティブ インク 骨に標的治療薬を送達するための組成物および方法
CN121772937A (zh) * 2023-05-30 2026-03-31 治疗调适公司 包含白细胞介素和钙化合物的用于治疗癌症的组合物
WO2025166305A1 (en) * 2024-02-02 2025-08-07 Theradaptive, Inc. Bone formation compositions and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1345246A (zh) * 1999-09-03 2002-04-17 安姆根有限公司 预防或治疗癌症及与癌症相关的骨损失的组合物和方法
WO2012078671A2 (en) * 2010-12-06 2012-06-14 Massachusetts Institute Of Technology Tricalcium phosphate binding peptides and use thereof

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US4880610A (en) 1988-04-20 1989-11-14 Norian Corporation In situ calcium phosphate minerals--method and composition
US5152791A (en) 1989-12-07 1992-10-06 Olympus Optical Co., Ltd. Prosthetic artificial bone having ceramic layers of different porosity
US5491082A (en) 1991-03-18 1996-02-13 Director-General Of Agency Of Industrial Science And Technology Plasminogen activator covalently bonded to a porous body of β-tricalcium phosphate
US7008634B2 (en) 1995-03-03 2006-03-07 Massachusetts Institute Of Technology Cell growth substrates with tethered cell growth effector molecules
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
US6455495B1 (en) 1997-02-14 2002-09-24 The Salk Institute For Biological Studies Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
AU770196B2 (en) 1999-02-04 2004-02-12 Warsaw Orthopedic, Inc. Osteogenic paste compositions and uses thereof
AU2001277854B2 (en) 2000-06-29 2007-03-01 North Shore-Long Island Jewish Health System Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
US6949251B2 (en) 2001-03-02 2005-09-27 Stryker Corporation Porous β-tricalcium phosphate granules for regeneration of bone tissue
US20040197892A1 (en) 2001-04-04 2004-10-07 Michael Moore Composition binding polypeptides
US20030113714A1 (en) 2001-09-28 2003-06-19 Belcher Angela M. Biological control of nanoparticles
WO2003072593A2 (en) 2002-02-21 2003-09-04 University Of Virginia Patent Foundation Bone targeting peptides
US20030221931A1 (en) 2002-02-28 2003-12-04 Steve Marsh Sliding device
US20050084962A1 (en) 2003-08-20 2005-04-21 Bruce Simon Methods of treatment using electromagnetic field stimulated stem cells
US7473682B2 (en) 2003-10-29 2009-01-06 Ramot At Tel Aviv University Ltd. Angiogenic peptides and uses thereof
US20060051396A1 (en) 2004-06-16 2006-03-09 Affinergy, Inc. Biofunctional coatings
WO2006012414A2 (en) 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Novel polyadenylation signal for use in expression vectors
US7871978B2 (en) 2004-11-04 2011-01-18 University Of Virginia Patent Foundation Bone tropic peptides
WO2006062776A2 (en) 2004-11-29 2006-06-15 The Regents Of The University Of California Hydroxyapatite-binding peptides for bone growth and inhibition
US20060193916A1 (en) 2005-01-07 2006-08-31 Acologix, Inc. Formulations of peptides for periodontal and dental treatments
US8137664B2 (en) 2005-02-02 2012-03-20 Sdgi Holdings, Inc. Method and kit for repairing a defect in bone
WO2007073661A1 (fr) * 2005-12-26 2007-07-05 Yantai Zhenghai Bio-Technology Co., Ltd. Matieres de squelette de collagene activees et leurs facteurs speciaux de restauration active fusionnee
US7592009B2 (en) 2006-10-10 2009-09-22 Ecole Polytechnique Federale De Lausanne (Epfl) Polypeptide ligands for targeting cartilage and methods of use thereof
US9295755B2 (en) 2006-10-18 2016-03-29 Wisconsin Alumni Research Foundation Multilayer tissue regeneration system
US7977313B2 (en) 2007-04-27 2011-07-12 Affinergy, Inc. Methods and compositions for promoting localization of pharmaceutically active agents to bone
US8075562B2 (en) 2007-06-25 2011-12-13 Wisconsin Alumni Research Foundation Controlled release of biopharmaceutical growth factors from hydroxyapatite coating on bioresorbable interference screws used in cruciate ligament reconstruction surgery
US20100098761A1 (en) 2007-08-03 2010-04-22 University Of Massachusetts Medical School Polymer Compositions For Biomedical And Material Applications
WO2009108934A2 (en) 2008-02-28 2009-09-03 Osteotherapeutics, L.L.C. Injectable calcium phosphate cememts formulated with bioactive agents and methods for making same
WO2009111014A2 (en) 2008-03-04 2009-09-11 Crystal Bioscience Inc. Gel microdrop composition and method of using the same
US8158366B2 (en) 2008-04-07 2012-04-17 Auburn University Methods of identifying peptides and compositions that bind to oocytes in a species-specific manner
US20100049322A1 (en) 2008-08-19 2010-02-25 Warsaw Orthopedic, Inc. Osteochondral repair implants and methods
GB0818255D0 (en) * 2008-10-06 2008-11-12 Agency Science Tech & Res Isolation and identification of glycosaminoglycans
CN104357381A (zh) 2008-10-31 2015-02-18 辛西斯有限责任公司 用于活化干细胞的方法和装置
WO2010052715A2 (en) 2008-11-07 2010-05-14 Ramot At Tel Aviv University Ltd. Devices and methods for local treatment of cardiovascular diseases
US20100260673A1 (en) 2009-04-10 2010-10-14 Qizhen Cao Phage display peptide probes for imaging early responses to antiangiogenic treatment
US8420774B2 (en) 2009-12-01 2013-04-16 Wisconsin Alumni Research Foundation Decorating hydroxyapatite biomaterials with modular biologically active molecules
WO2011116391A1 (en) 2010-03-19 2011-09-22 Lifenet Health Bmp-2 peptides & methods of use
US8778869B2 (en) 2010-06-09 2014-07-15 Wisconsin Alumni Research Foundation Tissue regeneration system
US20130268074A1 (en) 2010-12-21 2013-10-10 Prosthexis Pty Ltd Prosthetic menisci and method of implanting in the human knee joint
CN102532272A (zh) 2011-12-29 2012-07-04 陕西师范大学 HepG2细胞表面特异性结合的多肽
CN104193803B (zh) 2014-07-25 2016-08-17 河南科技大学 鸭肝炎病毒i型vp1蛋白抑制肽及其应用
US20160159869A1 (en) 2014-12-09 2016-06-09 Northwestern University Bmp-2-binding peptide amphiphile nanofibers
CN108473981B (zh) 2015-12-04 2022-04-12 卡里布生物科学公司 工程化靶向核酸的核酸
EP3631450B1 (en) 2017-05-29 2022-11-23 Charité - Universitätsmedizin Berlin Cd8 t cell subsets as a biomarker for predicting non-fusion after spinal fusion surgery
US10675330B2 (en) 2018-03-21 2020-06-09 Warsaw Orthopedic, Inc. Injectable bone morphogenetic protein
WO2019232283A1 (en) 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
CN110746500A (zh) 2018-07-24 2020-02-04 浙江瑞谷生物科技有限公司 一种编码重组人骨形态发生蛋白质-2的氨基酸序列
US20200102458A1 (en) 2018-09-28 2020-04-02 Icl Specialty Products Inc. Cool Roof Coating Containing Multifunctional Additive
CN113166202B (zh) * 2018-10-12 2024-09-13 治疗调适公司 包括β-磷酸三钙-结合序列的多肽及其用途
JP7128902B2 (ja) * 2018-12-25 2022-08-31 Ｏｒｔｈｏｒｅｂｉｒｔｈ株式会社 複数の電界紡糸繊維からなる綿形状の構造を有する骨再生用材料
US20220096600A1 (en) 2019-02-07 2022-03-31 Baylor College Of Medicine Periosteal skeletal stem cells in bone repair
US20220323641A1 (en) 2019-08-20 2022-10-13 Theradaptive, Inc. Materials for delivery of tetherable proteins in bone implants
US20230203115A1 (en) 2020-03-06 2023-06-29 Theradaptive, Inc. Therapeutic compositions comprising graft materials and beta-tcp binding peptides and uses thereof
JP2023525960A (ja) 2020-04-15 2023-06-20 セラダプティブ インク 骨に標的治療薬を送達するための組成物および方法
AU2021297422B2 (en) 2020-06-21 2023-12-14 Orthorebirth Co., Ltd. Osteoinductive bone regeneration material and production method of the same
WO2022182749A2 (en) 2021-02-24 2022-09-01 Theradaptive, Inc. Ceramic compositions and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1345246A (zh) * 1999-09-03 2002-04-17 安姆根有限公司 预防或治疗癌症及与癌症相关的骨损失的组合物和方法
WO2012078671A2 (en) * 2010-12-06 2012-06-14 Massachusetts Institute Of Technology Tricalcium phosphate binding peptides and use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120789330A (zh) * 2025-08-04 2025-10-17 中国人民解放军总医院第四医学中心 一种外科钛合金融合器活性涂层的制备方法

Also Published As

Publication number Publication date
WO2021211683A2 (en) 2021-10-21
WO2021211683A3 (en) 2021-11-18
AU2021254751B2 (en) 2025-01-30
TW202203961A (zh) 2022-02-01
KR20230011289A (ko) 2023-01-20
US20250179136A1 (en) 2025-06-05
JP2026004340A (ja) 2026-01-14
EP4135750A4 (en) 2024-08-21
BR112022020809A2 (pt) 2023-02-23
AU2021254751A1 (en) 2022-11-17
KR102821039B1 (ko) 2025-06-13
US20230235002A1 (en) 2023-07-27
CA3180156A1 (en) 2021-10-21
EP4135750A2 (en) 2023-02-22
US12264187B2 (en) 2025-04-01
JP2023525960A (ja) 2023-06-20

Similar Documents

Publication Publication Date Title
US11773138B2 (en) Polypeptides including a beta-tricalcium phosphate-binding sequence and uses thereof
KR102821039B1 (ko) 골에의 표적화된 치료적 전달을 위한 조성물 및 방법
US20040176287A1 (en) Bmp binding proteins for use in bone or cartilage regeneration
EP4017468A2 (en) Materials for delivery of tetherable proteins in bone implants
Kim et al. Promising efficacy of Escherichia coli recombinant human bone morphogenetic protein-2 in collagen sponge for ectopic and orthotopic bone formation and comparison with mammalian cell recombinant human bone morphogenetic protein-2
US20230203115A1 (en) Therapeutic compositions comprising graft materials and beta-tcp binding peptides and uses thereof
Seon et al. Peptide derived from stromal cell-derived factor 1δ enhances the in vitro expression of osteogenic proteins via bone marrow stromal cell differentiation and promotes bone formation in in vivo models
ES2382464T3 (es) Mutantes de factor del crecimiento de actividad elevada
HK40090498A (zh) 用於靶向治疗性递送至骨的组合物和方法
US9012401B2 (en) Growth factor mutants with improved biological activity
Masuda et al. Combined administration of BMP-2 and HGF facilitate bone regeneration through angiogenic mechanisms
Puleo Biotherapeutics in orthopaedic medicine: accelerating the healing process?
HK40056601B (zh) 包括β-磷酸三钙-结合序列的多肽及其用途
HK40056601A (en) Polypeptides including a beta-tricalcium phosphate-binding sequence and uses thereof
HK40098901A (zh) 骨形成促进材料
Barr Comparison of the Osteoinductivity of Infuse® and OP-1® via in vitro and in vivo Assays
Lee A Pilot Study to Compare the Activity of Different Bone Morphogenetic Protein Bioimplants In Vivo

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40090498

Country of ref document: HK